Last reviewed 2026-04-20 · How we verify

Campel (CHROMOCARB)

Phase 2 active Small molecule

Campel (generic name: CHROMOCARB) is a drug. It is currently in Phase 2 development.

Campel works by interacting with a specific biological target to produce a therapeutic effect.

Campel (CHROMOCARB) is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of Campel is unclear, and it is unknown whether it is patented or available as a generic. Key safety considerations for Campel are also unknown. Further research is needed to understand the pharmacology and clinical utility of this compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CHROMOCARB
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In plain English, Campel is a small molecule that binds to a specific protein or receptor in the body, which helps to regulate various cellular processes. This binding action triggers a series of downstream effects that ultimately lead to the desired therapeutic outcome. By modulating this biological pathway, Campel aims to treat a specific disease or condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Campel CI brief — competitive landscape report
Campel updates RSS · CI watch RSS

Frequently asked questions about Campel

What is Campel?

Campel (CHROMOCARB) is a Small molecule drug.

How does Campel work?

Campel works by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Campel?

CHROMOCARB is the generic (nonproprietary) name of Campel.

What development phase is Campel in?

Campel is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing